Buy Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (MPE8) (Human, IgG1, lambda2) for ELISA, SPR

Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (MPE8)

Catalog #: RVV02814 Specific References (8) DATASHEET

SDS-PAGE for Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (MPE8) ?>

Bioactivity for Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (MPE8) ?>

Host species: Human

Isotype: IgG1, lambda2

Applications: ELISA, SPR

Expression system: Mammalian Cells

Overview

Catalog No.

RVV02814

Description

This antibody neutralizes HRSV and HMPV isolates of several subgroups.

Expression system

Mammalian Cells

Species reactivity

Human respiratory syncytial virus A (strain A2),Human metapneumovirus

Host species

Human

Isotype

IgG1, lambda2

Clonality

Monoclonal

Target

F, Fusion glycoprotein F0, Protein F, CR13039

Concentration

3.78 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Applications

ELISA, SPR

Form

Liquid

Storage buffer

100 mM Pro-Ac, 20 mM Arg, pH 5.0

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

MPE8

Note

For research use only.

Data Image

SDS-PAGE

SDS PAGE for HRSV-A F/Fusion glycoprotein F0 Antibody (MPE8)
Bioactivity

Detects HRSV-A2 Pre-F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Detects HRSV Post-F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Detects HRSV F/Fusion glycoprotein F0 Protein in indirect ELISA.
Bioactivity

Fig 1. Epitope-specific antibodies (ESA) levels at sites Ⅱ, Ⅲ, Ⅳ, Ⅴ, and Ø Serum ESA levels, measured using competitive enzyme-linked immunosorbent assay (ELISA) [μg/mL], a re shown for antigenic sites Ⅱ (palivizumab), Ⅲ (MPE8), Ⅳ (clesrovimab), Ⅴ (suptavumab), and Ø (nirsevimab). Serum samples were collected from 92 healthy adults aged 28-75 yea rs (median, 41.5 yea rs) between Februa ry and Ma rch 2020. Significant differences were observed across all combinations of ESA concentrations (p<0.001 for a ll compa risons).
Data sourced from citation (PMID: 40675573)
Bioactivity

Figure S5. Binding of a panel of antibodies to DS1, DS2, and PF proteins both pre- and post-conjugation to PC7A/CpG. Antibody binding to DS1, DS2, and PF proteins before (A, C, and E) and after (B, D, and F) conjugation to PC7A/CpG was determined via indirect ELISA. The reactivities of PV2, MPE8, 101F, hRSV90, and 8897 were expressed as EC50 values corresponding to the concentration at which the half-maximum signal was obtained via ELISA, which was based on the optical density at 450 nm.
Data sourced from citation (PMID: DOI: 10.1002/adfm.202510925)
Bioactivity

Figure 4. 1G9 and 1D8 bind a similar epitope on Pre-F. (A, B) The competitive binding of Nbs 1G9 and 1D8 with six known epitope-specific antibodies. The values are normalized as competitive rates related to the negative control. Data represent the OD450 values measured and are depicted as the mean ± SD from three independent experiments. (C) The values in squares are the percent binding of the monoclonal antibody (IgG) in the presence of the competing Nbs (His-tag) relative to a mock-competition control. Source data are available online for this figure.
Data sourced from citation (PMID: 41946909)

References

Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein. [RVV02814]

A Self-Assembled RSV-DS2 Based Nanovaccine Elicits a Strong Immune Response Against Respiratory Syncytial Virus Infection. [RVV02814]

Respiratory Syncytial Virus Fusion Protein Epitope-specific Antibodies and Neutralizing Activities against Various Respiratory Syncytial Virus Strains. [RVV02814]

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization., PMID:2251875

Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage., PMID:1375280

Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic., PMID:11277694

Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection., PMID:29029312

Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response., PMID:33574352

Datasheet

Document Download

Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (MPE8).pdf

$ 372

Product specifications

100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here